There are 2949 resources available
Q&A and live discussion
Presenter: Samra Turajlic
Session: Proffered Paper - Translational research
Resources:
Webcast
Q&A and live discussion
Presenter: Evandro de Azambuja
Session: Proffered Paper - SARS-CoV-2 and cancer 1
Resources:
Webcast
CN29 - SARS-CoV-2 and the perspectives of people living with cancer: The AIIAO survey on the Italian lockdown
Presenter: Valentina Biagioli
Session: EONS13: Oncology care during Covid-19: How does it affect our patients
Resources:
Abstract
Webcast
LBA15 - Primary results from IMpassion131, a double-blind placebo-controlled randomised phase III trial of first-line paclitaxel (PAC) ± atezolizumab (atezo) for unresectable locally advanced/metastatic triple-negative breast cancer (mTNBC)
Presenter: David Miles
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA16 - IMpassion130: Final OS analysis from the pivotal phase III study of atezolizumab + nab-paclitaxel vs placebo + nab-paclitaxel in previously untreated locally advanced or metastatic triple-negative breast cancer
Presenter: Leisha Emens
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA17 - ASCENT: A randomized phase III study of sacituzumab govitecan (SG) vs treatment of physician’s choice (TPC) in patients (pts) with previously treated metastatic triple-negative breast cancer (mTNBC)
Presenter: Aditya Bardia
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA18 - Overall survival (os) results from SOLAR-1, a phase III study of alpelisib (ALP) + fulvestrant (FUL) for hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC)
Presenter: Fabrice André
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
273O - nextMONARCH: Final overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with HR+, HER2- metastatic breast cancer
Presenter: Erika Hamilton
Session: Proffered Paper - Breast cancer, metastatic 1
Resources:
Abstract
Slides
Webcast
LBA43 - Spartalizumab plus dabrafenib and trametinib (Sparta-DabTram) in patients (pts) with previously untreated BRAF V600–mutant unresectable or metastatic melanoma: Results from the randomized part 3 of the phase III COMBI-i trial
Presenter: Paul Nathan
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA44 - Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004
Presenter: Ana Maria Arance Fernandez
Session: Proffered Paper - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast